RxDoctor Payments Data

Raymond Howard, MD

Family Medicine · Belfast, MENPI 1295199719

Payments from drug & device makers

$734in general payments, 2019–2025

Across 13 payments — averaging $56.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$267
  • Myriad Genetic Laboratories, Inc.$189
  • AstraZeneca$125
  • Sun Pharmaceutical Industries Inc.$67
  • Dexcom, Inc.$44
  • Pfizer$22
  • plus $20 from 2 others

What the payments were for

  • Food & beverage$734100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$734 in reported general payments places this provider in the 85th percentile of 466 family medicine providers in Maine.

See all family medicine providers in Maine

Medicare billing

Part B allowed, 2024
$351
Medicare patients
30
Services billed
74

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban128$174,014
Cosentyx Sensoready (2 Pens)Secukinumab12$108,144
JardianceEmpagliflozin47$59,405
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$42,774
TrulicityDulaglutide37$39,976
OzempicSemaglutide33$34,810
Nurtec OdtRimegepant Sulfate12$22,090
Tresiba Flextouch U-200Insulin Degludec13$21,394
JanuviaSitagliptin Phosphate18$20,785
EntrestoSacubitril/Valsartan12$18,428
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$12,768
FarxigaDapagliflozin Propanediol13$12,042
MyrbetriqMirabegron13$10,720
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$10,112
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$7,936

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$22$196,103140 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$125$28,92246 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 466 family medicine providers in Maine.

Other family medicine in Belfast

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →